Recordati Bid Pulls Italian Pharma Deeper Into Private Equity Hands

The Recordati bid has pushed one of Italy’s best-known drugmakers into the center of Europe’s private equity deal cycle, after CVC Capital Partners and Groupe Bruxelles Lambert launched a cash offer worth about 10.7 billion euros to take the company private. The move gives investors a fresh test of how much value buyout firms still see in established pharmaceutical platforms with multiple growth levers.

The offer, announced on May 22, follows CVC’s March approach and comes with support from major existing and new shareholders. Reuters reported that the consortium is offering 51.29 euros a share ex dividend, while Recordati’s own disclosures confirmed the formal launch of the voluntary tender process, turning earlier speculation into a live transaction with clear thresholds, governance implications, and delisting ambitions.

Why the Deal Shifted From Approach to Formal Offer

The formal bid matters because it moves Recordati from a company subject to market rumor and preliminary interest into a structured takeover process. That shift changes the conversation from whether a buyout could happen to what kind of shareholder support, financing mix, and strategic logic will be needed to finish it.

It also matters because the buyers are not starting from zero. CVC already controls the vehicle that has held a large stake in Recordati since 2018, and the new consortium structure shows how private equity groups are building broader capital coalitions before trying to delist large European healthcare assets.

The Recordati Bid Turns a March Approach Into a Live Transaction

Reuters said the consortium launched a 10.7 billion euro cash bid on May 22, confirming the move through a new Italian joint stock company created for the offer. That is a materially different step from the non-binding expression of interest disclosed by Recordati on March 26, when CVC first signaled it wanted to buy the rest of the company and remove it from the Milan market.

The pricing also stayed intact. Reuters reported that the consortium confirmed the preliminary offer at 51.29 euros per share ex dividend, representing a 12.89% premium to Recordati’s March 25 share price, the day before the earlier approach became public. That preserved the headline economics while showing the bidders believed the original price was still sufficient to bring the process forward.

Recordati’s own site corroborated the new phase of the transaction with May 22 notices published on behalf of Respighi BidCo and on behalf of CVC and GBL. Even without a long operating update attached to those notices, the timing and sequencing are important because they show the company is now inside a formal tender framework rather than an open-ended strategic review.

Shareholder Math Sits at the Core of the Recordati Bid

The shareholder structure is central to the deal’s credibility. Reuters reported that Rossini, Recordati’s controlling shareholder, agreed to tender all of its shares, which account for 46.82% of the company. That support gives the bidder a powerful base before minority investors make their own decision.

The consortium is seeking at least a 66.67% voting stake, according to Reuters, because that level would provide control over shareholder resolutions requiring a qualified majority. In practice, that means the bid is not only about owning a larger economic stake. It is also about securing the legal and governance room needed to reshape the company’s future.

Reuters also said the bidders may pursue a merger by incorporation into the acquisition vehicle if acceptances do not reach the 90% threshold usually associated with a delisting path. That detail matters because it shows the buyers have mapped more than one route to control, reducing execution uncertainty even if some minority shareholders hold out for a sweeter price.

What CVC and GBL Would Be Buying

Recordati is not a single-product pharmaceutical story, which helps explain why a buyout consortium would treat it as more than a financial engineering exercise. The company combines specialty and primary care medicines, consumer health exposure, rare diseases, and a pharmaceutical chemicals business, giving investors several business lines with different margin, growth, and capital needs.

That mix also gives private owners more room to rethink priorities than they might have in a narrowly focused biotech company. A portfolio like Recordati can be optimized through acquisitions, disposals, sharper capital allocation, or a different balance between mature cash-generating assets and faster-growing specialty franchises.

The Recordati Bid Targets a Diversified Drug Platform

Reuters described Recordati as a company that started a century ago as a family pharmacy and now spans primary care, consumer health, and rare diseases. It also supplies other pharmaceutical companies through its chemicals division. That operating spread is part of the attraction because it gives buyers a platform that is already international and more diversified than many mid-cap drugmakers.

For Berrit Media readers, that matters because diversified healthcare companies often offer more strategic optionality than pure-play operators. A rare-disease franchise can command premium valuations, a primary-care business can throw off steadier cash flow, and a chemicals arm can add industrial resilience. Together, those businesses create multiple ways to unlock value if ownership changes.

The structure also helps explain why a consortium is involved instead of a lone sponsor. Different investors can underwrite different time horizons and return expectations across the same company. A broad shareholder base anchored by CVC and GBL gives the bidders room to support operating initiatives and acquisitions without forcing the entire investment case to rest on one asset class or one therapeutic theme.

Recent Results Gave the Recordati Bid a Stronger Operating Base

Recordati entered the deal process with current momentum rather than visible distress. In its May 12 first-quarter release, the company said net revenue rose 4.9%, EBITDA increased 5.0%, and adjusted net income climbed 7.2% in the opening quarter of 2026. Those numbers do not describe a business in retreat. They describe one still compounding while strategic ownership questions are being negotiated.

The company had also reported stronger full-year 2025 numbers earlier in March, including revenue of 2.6184 billion euros, EBITDA of 991.1 million euros, and adjusted net income of 651.1 million euros. Those figures give context to the buyout attempt because they show why buyers may be willing to pay for a stable, cash-generative pharmaceutical platform even after years of public-market ownership.

That performance backdrop is especially important for minority investors evaluating whether the current terms are enough. A company posting steady quarterly and annual growth can argue for patience and strategic upside, while buyers can argue that private ownership may allow faster action across the portfolio. The tension between those two views is likely to define the next phase of the Recordati bid.

Why This Matters Beyond One Italian Drugmaker

The transaction is not just a company-specific event. It also fits a broader pattern in which private capital is returning to healthcare assets that combine defensible cash flows with opportunities for bolt-on growth. In Europe, where sector fragmentation remains high in many niches, that combination can make listed mid-sized companies look especially attractive to consortium buyers.

Recordati also sits at the intersection of several themes Berrit Media tracks closely: take-private financing, healthcare consolidation, family-influenced ownership structures, and the question of whether public markets still reward diversified companies as generously as private sponsors believe they should. That is why the deal deserves attention beyond Milan’s trading session.

Italy’s Pharma Consolidation Wave Gives the Recordati Bid More Meaning

Reuters noted that Italy’s fragmented pharmaceutical sector has seen a burst of dealmaking in recent months as companies try to scale. It cited Angelini’s announced 4.1 billion dollar acquisition of Catalyst Pharmaceuticals and Chiesi’s purchase of KalVista Pharmaceuticals for about 2 billion dollars. Against that backdrop, the Recordati transaction looks less like an isolated balance-sheet event and more like part of a larger industry reordering.

Scale matters in pharmaceuticals for more than bragging rights. Larger platforms can spread regulatory, manufacturing, and commercial costs across more products, while acquisitions can fill geographic or therapeutic gaps faster than internal development alone. For private equity, fragmented markets create repeatable deal logic because the next acquisition can be framed as both growth and integration.

The Recordati bid therefore carries signal value for other European healthcare names. If this offer advances smoothly, it will reinforce the idea that buyout firms and long-duration capital partners still see room to build larger healthcare groups through a combination of public-to-private deals and targeted acquisitions across subsegments.

What the Recordati Bid Could Change Next

Reuters reported, citing a source with direct knowledge of the matter, that the plan to take Recordati private is meant to better explore options across its business lines, including potential new deals. That is the clearest clue yet that the buyers are thinking beyond ownership transfer and toward a more active portfolio strategy once the company is off the market, if the offer succeeds.

Not everyone is convinced the current price fully captures that upside. Reuters quoted Intermonte analyst Giorgio Tavolini as saying the offer did not look attractive for Recordati investors at the announced price and might need to be raised to secure a delisting. At the same time, he said the market price trading roughly in line with the offer suggested investors saw limited room for a materially higher sweetener.

That split captures the unresolved question at the heart of the deal. Is the Recordati bid mainly a pragmatic reshuffle among controlling shareholders, or is it the opening move in a more ambitious attempt to build a bigger private pharmaceutical platform? The answer will become clearer as acceptances, governance choices, and any post-offer strategic plans emerge in the weeks ahead.

The Recordati bid now stands as one of the most important current tests of private equity appetite for European healthcare platforms, and readers can continue following related investment and industry coverage at Berrit Media.